Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0CC8L
|
|||
Former ID |
DIB003019
|
|||
Drug Name |
CRILVASTATIN
|
|||
Synonyms |
Crilvastatin < Rec INN; PMD-387; L-Pyroglutamic acid rac-cis-3,3,5-trimethylcyclohexyl ester; 5-Oxo-L-proline rac-cis-3,3,5-trimethylcyclohexyl ester
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Phase 2 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C14H23NO3
|
|||
Canonical SMILES |
CC1CC(CC(C1)(C)C)OC(=O)C2CCC(=O)N2
|
|||
InChI |
1S/C14H23NO3/c1-9-6-10(8-14(2,3)7-9)18-13(17)11-4-5-12(16)15-11/h9-11H,4-8H2,1-3H3,(H,15,16)/t9?,10?,11-/m0/s1
|
|||
InChIKey |
FXAAOALUHHXBSO-ILDUYXDCSA-N
|
|||
CAS Number |
CAS 120551-59-9
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [2], [3] |
BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
Superpathway of cholesterol biosynthesis | ||||
Mevalonate pathway | ||||
KEGG Pathway | Terpenoid backbone biosynthesis | |||
Metabolic pathways | ||||
Biosynthesis of antibiotics | ||||
AMPK signaling pathway | ||||
Bile secretion | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
TSH Signaling Pathway | ||||
Panther Pathway | Cholesterol biosynthesis | |||
Pathwhiz Pathway | Steroid Biosynthesis | |||
WikiPathways | Statin Pathway | |||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
Activation of Gene Expression by SREBP (SREBF) | ||||
SREBF and miR33 in cholesterol and lipid homeostasis | ||||
Integrated Breast Cancer Pathway | ||||
SREBP signalling | ||||
Cholesterol Biosynthesis |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002276) | |||
REF 2 | Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol. 1996 Aug;118(7):1862-8. | |||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.